Ulla Hald Buhl
Director de Operaciones en CHOSA ONCOLOGY AB .
Cargos activos de Ulla Hald Buhl
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CHOSA ONCOLOGY AB | Director/Miembro de la Junta | 01/01/2023 | - |
| Director de Operaciones | 01/01/2023 | - | |
| Buhl Krone Holding ApS | Director Ejecutivo | - | - |
| Fundador | - | - |
Historial de carrera de Ulla Hald Buhl
Antiguos cargos conocidos de Ulla Hald Buhl.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CESSATECH A/S | Director/Miembro de la Junta | - | 01/01/2020 |
| Presidente | 01/01/2020 | 01/07/2021 | |
| Independent Dir/Board Member | 01/01/2020 | 01/07/2021 | |
Allarity Therapeutics Europe ApS
 Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Director/Miembro de la Junta | 01/03/2015 | 01/10/2019 |
| Director de Operaciones | 01/03/2012 | 01/10/2019 | |
| Contacto de Relaciones con Inversores | 01/03/2012 | 01/10/2019 | |
| Public Communications Contact | 01/03/2012 | 01/10/2019 | |
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Director de Operaciones | 01/01/2012 | 01/10/2019 |
Oncology Venture US, Inc.
 Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA. | Director/Miembro de la Junta | 01/12/2016 | 01/10/2019 |
| WNTRESEARCH AB | Corporate Officer/Principal | 01/01/2010 | 01/01/2016 |
Liplasome Pharma ApS
 Liplasome Pharma ApS Pharmaceuticals: MajorHealth Technology Liplasome Pharma ApS operates as a biotech company focusing on oncology. It develops drug delivery technologies for anticancer market. The firm's drug delivery platform consists of a lipid based drug delivery system for the intravenous transportation of anticancer drugs and prodrugs. The company was founded in 2002 and is headquartered in Hoersholm, Denmark. | Corporate Officer/Principal | 01/01/2010 | 01/01/2016 |
| TOPOTARGET A/S | Public Communications Contact | 01/01/2001 | - |
| ░░░░░░░░ ░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - | |
| ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | - | - | |
| ░░░░░░░ ░░░░░░░░░ ░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - | |
| ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | - | - |
Formación de Ulla Hald Buhl.
| University of Southern Denmark | Undergraduate Degree |
Estadísticas
Internacional
| Dinamarca | 10 |
| Suecia | 3 |
| Estados Unidos | 2 |
Operativa
| Chief Operating Officer | 5 |
| Director/Board Member | 5 |
| Public Communications Contact | 4 |
Sectorial
| Health Technology | 9 |
| Commercial Services | 3 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| WNTRESEARCH AB | Health Technology |
| CESSATECH A/S | Health Technology |
| CHOSA ONCOLOGY AB | Commercial Services |
| Empresas privadas | 8 |
|---|---|
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
Medical Prognosis Institute A/S
 Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark. | Health Technology |
Oncology Venture Sweden AB
 Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Health Technology |
Allarity Therapeutics Europe ApS
Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Health Technology |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
Oncology Venture US, Inc.
Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA. | Commercial Services |
| Buhl Krone Holding ApS | |
Liplasome Pharma ApS
Liplasome Pharma ApS Pharmaceuticals: MajorHealth Technology Liplasome Pharma ApS operates as a biotech company focusing on oncology. It develops drug delivery technologies for anticancer market. The firm's drug delivery platform consists of a lipid based drug delivery system for the intravenous transportation of anticancer drugs and prodrugs. The company was founded in 2002 and is headquartered in Hoersholm, Denmark. | Health Technology |
- Bolsa de valores
- Insiders
- Ulla Hald Buhl
- Experiencia
